Viewing data from:

WIXELA INHUB

ANDA

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE | A208891 | MYLAN PHARMACEUTICALS INC

3 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: ADVAIR DISKUS 100/50(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 3 NDCs

Highest NADAC/Unit

$1.61

per ea

Lowest NADAC/Unit

$1.14

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00378932232WIXELA 500-50 INHUB	$1.61	EA	Generic	—	2026-06-17
00378932132WIXELA 250-50 INHUB	$1.32	EA	Generic	—	2026-06-17
00378932032WIXELA 100-50 INHUB	$1.14	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 3 NDCs, 3 NC)

Lowest Price

$20.69

Highest Price

$26.57

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00378-9320-32WIXELA INHUB 100/50	$20.69	NC	Mylan Pharmaceuticals Inc.	07/31/2026
00378-9321-32WIXELA INHUB 250/50	$22.90	NC	Mylan Pharmaceuticals Inc.	07/31/2026
00378-9322-32WIXELA INHUB 500/50	$26.57	NC	Mylan Pharmaceuticals Inc.	07/31/2026

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data for Wixela Inhub (2024)

Total Spending

$196.5M

Total Claims

1,281,804

Beneficiaries

446,733

Avg Cost/Unit

$1.58

Spending Trend

$208.0M(2019)→$336.8M(2020)→$366.9M(2021)→$326.8M(2022)→$273.0M(2023)→$196.5M(2024)

YoY Change:-45.0%

5yr CAGR:-15.2%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Feb 21, 2019	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (3)

Sort:

#001 — 0.1MG/INH;EQ 0.05MG BASE/INH

0 patents0 exclusivities▴

POWDER;INHALATION | Approved: Jan 30, 2019

No patent or exclusivity listings for this strength.

#002 — 0.25MG/INH;EQ 0.05MG BASE/INH

0 patents0 exclusivities▾

POWDER;INHALATION | Approved: Jan 30, 2019

#003 — 0.5MG/INH;EQ 0.05MG BASE/INH

0 patents0 exclusivities▾

POWDER;INHALATION | Approved: Jan 30, 2019